Conectus
#CNS: Promising molecules seek talented industrialists!

Picto Conectus
Innovations Opportunités Partenariats Conectus Entreprises Recherche / Formation Socio-éco
Discover 2 promising assets, which will revolutionize the therapeutic treatment in neurodegenerative diseases. They are looking for industrial partners to bring them to clinical stage!
Bandeau_ATK et DELIS

These programs, named ATK and DELIS, come from renowned public research laboratories in  France.

ATK and DELIS programs have generated NCE that open up a therapeutic pathway for neurodegenerative pathologies without any therapeutic solution to date:

  • DISEASES TARGETED:
    Neurodegenerative diseases, especially:
    - Alzheimer's disease
    - Huntington's disease (ATK)
    - ALS et CIAS (DELIS)
     
  • MECHANISM OF ACTION:
    - ATK > TrkB PAM (Positive Allosteric Modulator) / first in class
    - DELIS > agoniste sigma1 / best in class potential
     
  • STATUS:
    - hit to lead opportunity (SAR and first optimization round)
    - in vitro caracterization ADME/TOX
    - PK et in vivo tox profile
    - in vivo POC
Strengths!

+++ NCE, first and best in class
+++ Strong potential in orphan diseases with no therapeutic solutions
+++ Patented and derisked
+++ Wide application potential  

ARE YOU A STARTUP, A BIOTECH COMPANY OR A BIG PHARMA ? 

YOU CAN :

  • take a licence for both molecules or only one
  • benefit from an exclusive and worlwide exploitation rights
  • connect and collaborate directly with the researchers-inventors, experts in the targets
     

IN ADDITION!
The licensing process of these technologies will be fully managed by SATT CONECTUS (French TTO). You will have a single point of contact throughout the transfer process.

Info +

Interested? 
Please contact: celine.nadin@satt.conectus.fr  

Do you really want to remove this technology from your list ?
close